The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Preclinical Evidence for the Use of Brexpiprazole + Antidepressant Treatment for Major Depressive Disorder and Post-Traumatic Stress Disorder: A Systematic Review
Open accessAbstract
Purpose: Brexpiprazole, when administered with antidepressant therapy, may provide additional benefits due to complementary actions on noradrenaline (norepinephrine), serotonin, and dopamine neurotransmitter systems. This review addressed the question: what information can preclinical studies provide on the use of brexpiprazole + antidepressant treatment? Methods: A systematic literature review was conducted to search for preclinical studies of brexpiprazole + antidepressant therapy that included a behavioral test relating to any psychiatric disorder. Ovid MEDLINE, Ovid Embase, and conference abstracts were searched (January 1, 2011–July 5, 2021). The statistically significant (p< 0.05) findings for brexpiprazole + antidepressant were extracted. Results: Of 296 records screened, nine articles were eligible, describing seven unique studies. In rodent models, including three models of depression (unpredictable chronic mild stress, social defeat stress, and lipopolysaccharide-induced depression), brexpiprazole + selective serotonin reuptake inhibitor (SSRI) or serotonin–noradrenaline reuptake inhibitor (SNRI) consistently showed statistically significant benefits over vehicle on depression-like behaviors (forced swim test, tail suspension test, sucrose preference), whereas brexpiprazole and antidepressant monotherapies did not. In the predator scent stress model of post-traumatic stress disorder (PTSD), brexpiprazole + SSRI (escitalopram) showed a significant benefit over vehicle and/or monotherapy on anxiety-like behaviors (elevated plus-maze) and hyperalertness (acoustic startle response), whereas brexpiprazole and escitalopram monotherapies did not significantly differ from vehicle. In the fear conditioning model of PTSD, brexpiprazole showed significant improvements whether administered as monotherapy or in combination with escitalopram. Conclusion: Based on a small number of studies, the administration of brexpiprazole with an antidepressant appears to have a greater treatment effect than either brexpiprazole or antidepressant monotherapies in preclinical studies of depression- and PTSD-like behaviors. Thus, preclinical studies support evidence from randomized clinical trials for the therapeutic effects of adjunctive brexpiprazole in the treatment of major depressive disorder, and brexpiprazole in combination with sertraline in the treatment of PTSD. Funding: Otsuka/Lundbeck. Plain Language Summary: Studies of medications in animals can provide additional information to complement studies in humans. This review investigates what can be learned from animal studies of brexpiprazole (a medication known as an “atypical antipsychotic”) given together with an antidepressant medication. Seven animal studies that assess brexpiprazole + antidepressant treatment in rat or mouse models of depression and post-traumatic stress disorder were identified. Overall, these animal studies provide support for the observed benefits of brexpiprazole added to antidepressant treatment in major depressive disorder, and the ongoing development of brexpiprazole + antidepressant as a potential combination treatment for post-traumatic stress disorder. Keywords: antidepressants, antipsychotics, depression, PTSD, behavior rating scale
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“case series combining brexpiprazole with ketamine or esketamine suggest rapid clinical recovery in complex presentations and motivate controlled multimodal trials [388].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [388]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Page, M. J., Moher, D., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n160 · Cited by 13,262 · cited 2×
“55 In Study 1, 25 marbles were evenly spaced on a layer of sawdust in a cage, and the number of marbles more than two thirds covered by sawdust after 30 minutes was counted, 28,29 where a lower number of buried marbles indicates a stronger therapeutic effect.”
Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat
Pellow, S., Chopin, P., File, S. E., & Briley, M. (1985) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(85)90031-7 · Cited by 5,822
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
SYRCLE’s risk of bias tool for animal studies
Hooijmans, C. R., Rovers, M. M., de Vries, R. B., Leenaars, M., Ritskes-Hoitinga, M., & Langendam, M. W. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-43 · Cited by 4,415
Behavioral despair in mice: a primary screening test for antidepressants.
Porsolt, R. D., Bertin, A., & Jalfre, M. (1977) · PubMed · Cited by 3,320
Behavioural despair in rats: A new model sensitive to antidepressant treatments
Porsolt, R. D., Anton, G., Blavet, N., & Jalfre, M. (1978) · European Journal of Pharmacology · doi:10.1016/0014-2999(78)90118-8 · Cited by 3,138
Willner, P., Towell, A., Sampson, D., Sophokleous, S., & Muscat, R. (1987) · Psychopharmacology · doi:10.1007/bf00187257 · Cited by 1,993
A standardized protocol for repeated social defeat stress in mice
Golden, S. A., Covington, H. E., Berton, O., & Russo, S. J. (2011) · Nature Protocols · doi:10.1038/nprot.2011.361 · Cited by 1,581
Chronic mild stress-induced anhedonia: A realistic animal model of depression
Willner, P., Muscat, R., & Papp, M. (1992) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(05)80194-0 · Cited by 1,160 · cited 2×
“39,40 In the SDS model, C57BL/6 mice are repeatedly exposed to larger CD1 mice that have been screened for aggressive behavior.”
Cryan, J. F., Valentino, R. J., & Lucki, I. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.03.008 · Cited by 1,119
Sucrose preference test for measurement of stress-induced anhedonia in mice
Liu, M.-Y., Yin, C.-Y., Zhu, L.-J., Zhu, X.-H., Xu, C., Luo, C.-X., Chen, H., Zhu, D.-Y., & Zhou, Q.-G. (2018) · Nature Protocols · doi:10.1038/s41596-018-0011-z · Cited by 1,026
Kilkenny, C., Parsons, N., Kadyszewski, E., Festing, M. F. W., Cuthill, I. C., Fry, D., Hutton, J., & Altman, D. G. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007824 · Cited by 860
A simple and reliable conflict procedure for testing anti-anxiety agents
Vogel, J. R., Beer, B., & Clody, D. E. (1971) · Psychopharmacologia · doi:10.1007/bf00403989 · Cited by 841
Post-traumatic stress disorder: the neurobiological impact of psychological trauma
Sherin, J. E., & Nemeroff, C. B. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.2/jsherin · Cited by 750
Castagné, V., Moser, P., Roux, S., & Porsolt, R. D. (2011) · Current Protocols in Neuroscience · doi:10.1002/0471142301.ns0810as55 · Cited by 702
Flory, J. D., & Yehuda, R. (2015) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2015.17.2/jflory · Cited by 629
Anhedonia and motivational deficits in rats: Impact of chronic social stress
Rygula, R., Abumaria, N., Flügge, G., Fuchs, E., Rüther, E., & Havemann-Reinecke, U. (2005) · Behavioural Brain Research · doi:10.1016/j.bbr.2005.03.009 · Cited by 554
Is there a role for 5-HT1A agonists in the treatment of depression?
Blier, P., & Ward, N. M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01643-8 · Cited by 529
Evaluation of marble-burying behavior as a model of anxiety
Njung'e, K., & Handley, S. L. (1991) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(91)90590-x · Cited by 487
Animal models of major depression: drawbacks and challenges
Planchez, B., Surget, A., & Belzung, C. (2019) · Journal of Neural Transmission · doi:10.1007/s00702-019-02084-y · Cited by 480
Singewald, N., Schmuckermair, C., Whittle, N., Holmes, A., & Ressler, K. J. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.004 · Cited by 390 · cited 1×
“…studies support a greater effect of brexpiprazole + antidepressant therapy versus the respective monotherapies in various validated (with regard to etiology, symptomatology, and treatment response 67–69 ) behavioral models and tests of treatment effects on depression-and PTSD-like behaviors.”
Arnsten, A. F. T., Raskind, M. A., Taylor, F. B., & Connor, D. F. (2015) · Neurobiology of Stress · doi:10.1016/j.ynstr.2014.10.002 · Cited by 381
The importance of norepinephrine in depression
Briley, M., & Chantal, M. (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s19619 · Cited by 373
Maeda, K., Sugino, H., Akazawa, H., Amada, N., Shimada, J., Futamura, T., Yamashita, H., Ito, N., McQuade, R. D., Mørk, A., et al. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.213793 · Cited by 372
Kane, J. M., Skuban, A., Ouyang, J., Hobart, M., Pfister, S., McQuade, R. D., Nyilas, M., Carson, W. H., Sanchez, R., & Eriksson, H. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.01.038 · Cited by 325
Serotonin receptors involved in antidepressant effects
Artigas, F. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.09.006 · Cited by 311
(1990) · American Journal of Psychiatry · doi:10.1176/ajp.147.10.1308 · Cited by 273
The relevance of differential response to trauma in an animal model of posttraumatic stress disorder
Cohen, H., Zohar, J., & Matar, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01909-1 · Cited by 268
Glucocorticoids Can Induce PTSD-Like Memory Impairments in Mice
Kaouane, N., Porte, Y., Vallée, M., Brayda-Bruno, L., Mons, N., Calandreau, L., Marighetto, A., Piazza, P. V., & Desmedt, A. (2012) · Science · doi:10.1126/science.1207615 · Cited by 250
Deslauriers, J., Toth, M., Der-Avakian, A., & Risbrough, V. B. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.11.019 · Cited by 250
Physiologic Responses to Loud Tones in Israeli Patients With Posttraumatic Stress Disorder
Shalev, A. Y. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110034005 · Cited by 236
Porsolt, R. D., Brossard, G., Hautbois, C., & Roux, S. (2001) · Current Protocols in Neuroscience · doi:10.1002/0471142301.ns0810as14 · Cited by 210
Ohgi, Y., Futamura, T., Kikuchi, T., & Hashimoto, K. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.12.003 · Cited by 207
Luo, Y., Kataoka, Y., Ostinelli, E. G., Cipriani, A., & Furukawa, T. A. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00035 · Cited by 206 · cited 1×
“18 The most commonly prescribed antidepressant classes (SSRIs, serotonin–noradrenaline reuptake inhibitors [SNRIs], and noradrenaline–dopamine reuptake inhibitors [NDRIs] 19 ) act primarily on one or two monoamine systems.”
Emotional blunting with antidepressant treatments: A survey among depressed patients
Goodwin, G. M., Price, J., De Bodinat, C., & Laredo, J. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.05.048 · Cited by 202
Cools, R., & Arnsten, A. F. T. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-021-01100-8 · Cited by 202
Correll, C. U., Skuban, A., Ouyang, J., Hobart, M., Pfister, S., McQuade, R. D., Nyilas, M., Carson, W. H., Sanchez, R., & Eriksson, H. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.14101275 · Cited by 183
Thase, M. E., Youakim, J. M., Skuban, A., Hobart, M., Augustine, C., Zhang, P., McQuade, R. D., Carson, W. H., Nyilas, M., Sanchez, R., et al. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09688 · Cited by 182 · cited 4×
“Thus, preclinical studies support evidence from randomized clinical trials for the antidepressant effects of adjunctive brexpiprazole in MDD, 3–6 and the efficacy of brexpiprazole in combination with the SSRI, sertraline, in PTSD. 9,10 Furthermore, the preclinical evidence from this review highlights the value of this…”
InfluentialNjung'e, K., & Handley, S. L. (1991) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1991.tb12392.x · Cited by 182
Fluoxetine: a case history of its discovery and preclinical development
Perez-Caballero, L., Torres-Sanchez, S., Bravo, L., Mico, J. A., & Berrocoso, E. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.907790 · Cited by 178
The Vogel conflict test: procedural aspects, γ-aminobutyric acid, glutamate and monoamines
Millan, M. J., & Brocco, M. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01275-5 · Cited by 177
ROBINSON, D. S., RICKELS, K., FEIGHNER, J., FABRE, L. F., GAMMANS, R. E., SHROTRIYA, R. C., ALMS, D. R., ANDARY, J. J., & MESSINA, M. E. (1990) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199006001-00013 · Cited by 173
Second-generation antipsychotics for major depressive disorder and dysthymia
Komossa, K., Depping, A. M., Gaudchau, A., Kissling, W., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008121.pub2 · Cited by 171
Grossberg, G. T., Kohegyi, E., Mergel, V., Josiassen, M. K., Meulien, D., Hobart, M., Slomkowski, M., Baker, R. A., McQuade, R. D., & Cummings, J. L. (2020) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.09.009 · Cited by 169
Pharmacotherapy for post traumatic stress disorder (PTSD)
Williams, T., Phillips, N. J., Stein, D. J., & Ipser, J. C. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002795.pub3 · Cited by 167
Thase, M. E., Youakim, J. M., Skuban, A., Hobart, M., Zhang, P., McQuade, R. D., Nyilas, M., Carson, W. H., Sanchez, R., & Eriksson, H. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09689 · Cited by 165
Inflammation Models of Depression in Rodents: Relevance to Psychotropic Drug Discovery
Remus, J. L., & Dantzer, R. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw028 · Cited by 164
Taylor, F., & Raskind, M. A. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200202000-00013 · Cited by 161
Pharmacologic Reduction of CNS Noradrenergic Activity in PTSD: The Case for Clonidine and Prazosin
Boehnlein, J. K., & Kinzie, J. D. (2007) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000265763.79753.c1 · Cited by 148
Azapirones for generalized anxiety disorder
Chessick, C. A., Allen, M. H., Thase, M. E., Batista Miralha da Cunha, A. A., Kapczinski, F., Silva de Lima, M., & dos Santos Souza, J. J. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006115 · Cited by 144
Maeda, K., Lerdrup, L., Sugino, H., Akazawa, H., Amada, N., McQuade, R. D., Stensbøl, T. B., Bundgaard, C., Arnt, J., & Kikuchi, T. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.213819 · Cited by 144
Memory Mechanisms in Posttraumatic Stress Disorder
Layton, B. S., & Krikorian, R. (2002) · Journal of Neuropsychiatry · doi:10.1176/jnp.14.3.254 · Cited by 141
Brexpiprazole for the Treatment of Agitation in Alzheimer Dementia: A Randomized Clinical Trial
Lee, D., Slomkowski, M., Hefting, N., Chen, D., Larsen, K. G., Kohegyi, E., Hobart, M., Cummings, J. L., & Grossberg, G. T. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.3810 · Cited by 135
Waterhouse, B. D., & Navarra, R. L. (2018) · Brain Research · doi:10.1016/j.brainres.2018.08.032 · Cited by 130
Models of Depression: Unpredictable Chronic Mild Stress in Mice
Nollet, M. (2021) · Current Protocols · doi:10.1002/cpz1.208 · Cited by 122
Advantages and Limitations of Animal Schizophrenia Models
Białoń, M., & Wąsik, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23115968 · Cited by 111
Pharmacotherapy for post traumatic stress disorder (PTSD)
Williams, T., Phillips, N. J., Stein, D. J., & Ipser, J. (2026) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002795.pub4 · Cited by 100
Second-generation antipsychotics in the treatment of major depressive disorder: current evidence
Han, C., Wang, S., Kato, M., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2013.811901 · Cited by 99
Uys, M. M., Shahid, M., & Harvey, B. H. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00144 · Cited by 90
Psychiatric symptoms of noradrenergic dysfunction: A pathophysiological view
Yamamoto, K., Shinba, T., & Yoshii, M. (2014) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12126 · Cited by 88
Generalized fear after acute stress is caused by change in neuronal cotransmitter identity
Li, H.-Q., Jiang, W., Ling, L., Gupta, V., Chen, C., Gupta, V., Godavarthi, S. K., & Spitzer, N. C. (2024) · Science · doi:10.1126/science.adj5996 · Cited by 75
The noradrenergic symptom cluster: clinical expression and neuropharmacology
Briley, M., & Blier, P. (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s19613 · Cited by 74
Ma, M., Ren, Q., Yang, C., Zhang, J.-C., Yao, W., Dong, C., Ohgi, Y., Futamura, T., & Hashimoto, K. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4483-7 · Cited by 72
Hobart, M., Skuban, A., Zhang, P. G. Y., Augustine, C., Brewer, C., Hefting, N., Sanchez, R., & McQuade, R. D. (2018) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.17m12058 · Cited by 71
Theory of active antidepressants: A nonsynaptic approach to the treatment of depression
Kiss, J. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.04.006 · Cited by 70
Hobart, M., Skuban, A., Zhang, P. G. Y., Josiassen, M. K., Hefting, N., Augustine, C., Brewer, C., Sanchez, R., & McQuade, R. D. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1430220 · Cited by 70
Citrome, L., Stensbøl, T. B., & Maeda, K. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1086269 · Cited by 63
Self-citationEffects of antipsychotics and reference monoaminergic ligands on marble burying behavior in mice
Slot, L. A. B., Bardin, L., Auclair, A. L., Depoortère, R., & Newman‐Tancredi, A. (2008) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3282f62cb2 · Cited by 63
Ma, M., Ren, Q., Yang, C., Zhang, J.-C., Yao, W., Dong, C., Ohgi, Y., Futamura, T., & Hashimoto, K. (2016) · Scientific Reports · doi:10.1038/srep39209 · Cited by 62
Therapeutic Challenges of Post-traumatic Stress Disorder: Focus on the Dopaminergic System
Torrisi, S. A., Leggio, G. M., Drago, F., & Salomone, S. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00404 · Cited by 62
Bourin, M., Chenu, F., Prica, C., & Hascoët, M. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1583-7 · Cited by 59
Animal models of psychiatric disorders and their relevance to alcoholism.
Hitzemann, R. (2000) · PubMed Central · Cited by 58
LHRH antagonist attenuates the effect of fluoxetine on marble-burying behavior in mice
Gaikwad, U., Bhutada, P., Manish, W., & Umathe, S. N. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.02.016 · Cited by 54
Dong, C., Zhang, J.-C., Yao, W., Ren, Q., Yang, C., Ma, M., Han, M., Saito, R., & Hashimoto, K. (2016) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2016.02.005 · Cited by 53
van der Naald, M., Wenker, S., Doevendans, P. A., Wever, K. E., & Chamuleau, S. A. J. (2020) · BMJ Open Science · doi:10.1136/bmjos-2019-100051 · Cited by 53
Selective serotonin reuptake inhibitors-associated apathy syndrome
Padala, P. R., Padala, K. P., Majagi, A. S., Garner, K. K., Dennis, R. A., & Sullivan, D. H. (2020) · Medicine · doi:10.1097/md.0000000000021497 · Cited by 49
Vogel conflict test: Sex differences and pharmacological validation of the model
Basso, A. M., Gallagher, K. B., Mikusa, J. P., & Rueter, L. E. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.11.041 · Cited by 46
Wieschowski, S., Biernot, S., Deutsch, S., Glage, S., Bleich, A., Tolba, R. H., & Strech, D. (2019) · PLoS ONE · doi:10.1371/journal.pone.0223758 · Cited by 45
Cohen, H., Matar, M., & Zohar, J. (2014) · ILAR Journal · doi:10.1093/ilar/ilu006 · Cited by 38
Cohen, H., Zohar, J., Kaplan, Z., & Arnt, J. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.11.017 · Cited by 38
McIntyre, R. S., Weiller, E., Zhang, P., & Weiss, C. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.05.013 · Cited by 36
Cummings, J. L., Brubaker, M., Selzler, K. J., Gonzalez, S. T., Patel, M., & Stahl, S. M. (2024) · CNS Spectrums · doi:10.1017/s1092852924000427 · Cited by 35
Self-citationThase, M. E., Weiller, E., Zhang, P. G. Y., Weiss, C., & McIntyre, R. S. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s185815 · Cited by 31
Thase, M. E., Zhang, P. G. Y., Weiss, C., Meehan, S. R., & Hobart, M. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1638913 · Cited by 31
Brexpiprazole blocks post-traumatic stress disorder-like memory while promoting normal fear memory
Ducourneau, E., Guette, C., Perrot, D., Mondésir, M., Mombereau, C., Arnt, J., Desmedt, A., & Piazza, P. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0852-z · Cited by 24
Jain, R., Chepke, C., Davis, L. L., McIntyre, R. S., & Raskind, M. A. (2024) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.plunaro2417ah · Cited by 22
Davis, L. L., Behl, S., Lee, D. J., Zeng, H., Skubiak, T., Weaver, S., Hefting, N., Larsen, K. G., & Hobart, M. (2024) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2024.3996 · Cited by 22
Aftab, A., & Gao, K. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1354849 · Cited by 15
D, M. F. M., Weiller, E., Zhang, P. G. Y., & Weiss, C. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000678 · Cited by 13
Katzman, M. A., Therrien, F., MacKenzie, E. M., Wang, F., de Jong-Laird, A., & Boucher, M. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.08.021 · Cited by 12
Amada, N., Hirose, T., Suzuki, M., Kakumoto, Y., Futamura, T., Maeda, K., & Kikuchi, T. (2023) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12316 · Cited by 12
McIntyre, R. S., Bubolic, S., Zhang, Z., MacKenzie, E. M., Therrien, F., Miguelez, M., & Boucher, M. (2024) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001825 · Cited by 11
Davis, L. L., Urganus, A., Gagnon-Sanschagrin, P., Maitland, J., Qu, W., Cloutier, M., Guérin, A., & Aggarwal, J. (2023) · Current Medical Research and Opinion · doi:10.1080/03007995.2023.2269839 · Cited by 6
Improving Translational Relevance in Preclinical Psychopharmacology (iTRIPP)
Bailey, S., Bast, T., Chaby, L. E., Kinon, B. J., Harte, M., Mead, S., Moloney, R. D., Ragan, I., Stanford, S. C., Tricklebank, M. D., et al. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231182607 · Cited by 5
Hobart, M., Chang, D., Hefting, N., & Davis, L. L. (2025) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.24m15577 · Cited by 5
Amada, N., Sato, S., Ishikawa, D., Nakamura, M., Suzuki, M., Futamura, T., & Maeda, K. (2024) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12461 · Cited by 4
AKSÖZ, E., Karson, A., ŞAHİN, T. D., & Utkan, T. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.03.008 · Cited by 1
Brain Structural Correlates of Sensory Phenomena in Obsessive-Compulsive Disorder
Subirà, M., Sato, J. R., Batistuzzo, M. C., Alonso, P., Lopes, A. C., Segalàs, C., Shavitt, R. G., Real, E., Assis, R. O., Cerrillo, E., et al. (2014) · UNIFESP Institutional Repository (Universidade Federal de São Paulo) · doi:10.1016/j.biopsych.2014.03.014
Research works printed but not linked: 7
- 2013, Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications
- Hitzemann, 2000, Alcohol Res Health, 24, 149
- Maeda K, Stensbøl TB, Akazawa H, et al. Pharmacological profile of brexpiprazole (OPC-34712): a novel serotonin–dopamine activity modulator. Poster presented at: American Psychiatric Association 167th Annual Meeting; 2014; New York, NY. Available from: https://www.psychiatry.org/Psychiatrists/Search-Directories-Databases/Conference-Publications/2014/2014-Annual-Meeting-Posters-New-Research-Abstracts. Accessed August 3, 2024.
- Lerdrup L, Maeda K, Stensbøl TB. Brexpiprazole shows antidepressant- and anxiolytic-like effects in the rat forced swim and Vogel conflict tests. Poster presented at: American Psychiatric Association 168th Annual Meeting; 2015; Toronto, Canada. Available from: https://www.psychiatry.org/Psychiatrists/Search-Directories-Databases/Conference-Publications/2015/2015-Annual-Meeting-Posters-New-Research-Abstracts. Accessed August 3, 2024.
- Porsolt, 1977, Arch Int Pharmacodyn Ther, 229, 327
- 2009, Methods of Behavior Analysis in Neuroscience
- 2015, Fluoxetine: Pharmacology, Mechanisms of Action and Potential Side Effects
Cited by
Mechanisms of flame retardant toxicity and their impacts on anxiety and cognition in the brain
Rojas, C. M., Wiersielis, K. R., & Roepke, T. A. (2025) · Endocrinology · doi:10.1210/endocr/bqaf074 · Cited by 10
Stroud, J., Cummings, J. L., Chumki, S. R., Such, P., Wang, D., Palma, A. M., Zhang, Z., Brubaker, M., & Grossberg, G. T. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2552278 · Cited by 10
Self-citationAlissa, M., Alghamdi, S. A., Binshaya, A. S., Juraybi, T. N., Safhi, A. Y., Albati, A. A., Abalkhail, A., & Alqarni, A. M. (2026) · Tissue and Cell · doi:10.1016/j.tice.2026.103340 · Cited by 2
Kotochinsky, M., Alessi, M. R., Vieira, G. H., Balogun, M., Sherpa, N. N., & Lezana, A. G. (2025) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.10.063 · Cited by 1
Danek, P. J., Pukło, R., & Daniel, W. A. (2026) · Pharmacological Reports · doi:10.1007/s43440-026-00859-1 · Cited by 1
Metadata
- Authors
- Brubaker, M., Kapadia, S., Maletic, V., Chambers, J., Watling, C., & Citrome, L.
- Affiliations
- Otsuka (United States) (US)
- University of South Carolina (US)
- New York Medical College (US)
- Corresponding author
- Brubaker, Malaak
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2025-02
- Volume
- Volume 21
- Pages
- 421-436
- ISSN
- 1176-6328 (ISSN-L)
- 1178-2021
- PMC
- PMC11878111
- OpenAlex
- W4408033871
- Cited by
- 7
- References
- 98
- Citations by year
- 2026: 4 · 2025: 3
- FWCI
- 0.95
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Neuropsychiatric Disease and Treatment (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (acceptedVersion, other-oa)
- Touro Scholar (Touro College) (submittedVersion, cc-by-nc)
- Funders
- Otsuka Pharmaceutical
- H. Lundbeck A/S
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- brexpiprazole, major depressive disorder, post-traumatic stress disorder, antidepressant combination therapy, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, escitalopram, sertraline, rodent models of depression, social defeat stress, chronic unpredictable mild stress, lipopolysaccharide-induced depression, fear conditioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
